Last week's top 10 Penny stocks generated significant returns, providing shareholders with strong gains with very little upfront investment.
Ekso Bionics Holdings Inc
I write today with one very important question on my mind: Did I help you make money in 2017?
I'm asking because I'm a firm believer in taking my own advice.
I counsel you to take a good hard look at the strategies you use, at your investments, and at your analysis, so it only makes sense that I do the same.
Some people call this "transparency," but I call it "owning up."
Frankly, I wish more investment experts would own up – warts and all – because that'd go a long way to cleaning up Wall Street. Sadly, there's a snowball's chance in you know what because they're too busy trying to steer you in a direction that boosts their profits at your expense.
The way I see it, integrity is everything in this business. I don't deserve the trust you place in me if I'm not helping you chart a path to profits.
SemiLEDS Corp. is among the top penny stocks to watch this week, after climbing an astounding 142% last week.
While that’s an impressive gain, we’re recommending a different stock to our readers. This stock not only has the potential for even bigger returns than LEDS, but it’s also less volatile.
The company we’ll show you today has beaten analyst earnings expectations in six of the last seven quarters and is on pace to grow profits by 33% or more this year.
In November, penny stocks have posted massive triple-digit gains.
As you can see in our list, the top penny stock of the month is already up 384%.
The minimum wage debate has run its course – whether investors, pundits, and politicians like it or not.
Because there's no denying (and no stopping) what's about to upend the entire U.S. workforce as we know it.
For all the success we've had together and the countless recommendations along the way that have given you huge profit potential, we've hit a stinker.
To say I'm disappointed with Ekso Bionics' latest numbers would be the understatement of the year.
The company reported financial results for the first three months of 2017, and revenue dropped off a cliff from $8.5 million a year ago to only $1.4 million this year. Granted, last year's figures included recognition of a deferred $6.5 million worth of revenue due to an accounting change, but that doesn't change the fact that sales tanked.
Every company reaches a "make or break" moment – meaning the precise instant in time when it will become a hero or a zero.
I've spent the past few days hunkered down in my office poring over reams of information, and there's no doubt in my mind that's where we are with Ekso Bionics Holdings Ltd. (NasdaqCM:EKSO).
The conclusion I've reached may surprise you.
It's an update neither you nor your wallet want to miss.
In his latest Ekso Bionics stock update, our expert breaks down the company's latest numbers.